Prostate cancer detection strategies

Current Urology Reports

Volumn 7, Issue 3, 2006, Pages 181-185

  Brand, Timothy C ^a   Hernandez, Javier ^b   Canby Hagino, Edith D ^b   Basler, Joseph W ^b   Thompson, Ian M ^b  

^a University of Texas Health Science Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

BLOOD LEVEL; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; DIGITAL RECTAL EXAMINATION; DNA POLYMORPHISM; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; URINALYSIS;

GENETIC MARKERS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33750377751     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-006-0019-8     Document Type: Review

References (63)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Thompson I, Tangen C, Tolcher A, et al.: Association of African-American ethnic background with survival in men with metastatic prostate cancer [see comment]. J Natl Cancer Inst 2001, 93:219-225.
3. McDavid K, Lee J, Fulton JP, et al.: Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004, 119:174-186.
4. Edwards BK, Brown ML, Wingo PA, et al.: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407-1427.
5. Surveillance Epidemiology and End Results. Edited by US National Institute of Health, 2005. www.seer.cancer.gov. Accessed March 8, 2006.
6. Kuriyama M, Takeuchi T, Okano M, et al.: [A normal value of serum prostate antigen in Japanese males and its comparison with Americans]. Nippon Hinyokika Gakkai Zasshi 1984, 75:802-806.
7. Chodak GW, Schoenberg HW: Early detection of prostate cancer by routine screening. JAMA 1984, 252:3261-3264.
8. Ablin RJ, Bronson P, Soanes WA, Witebsky E: Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 1970, 104:1329-1339.
9. Ablin RJ, Soanes WA, Bronson P, Witebsky E: Precipitating antigens of the normal human prostate. J Reprod Fertil 1970, 22:573-574.
10. Kobayashi T, Nishizawa K, Ogura K, et al.: Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population. Urology 2004, 63:727-731.
11. Babaian RJ, Johnston DA, Naccarato W, et al.: The incidence of prostate cancer in a screening population with a serum prostate-specific antigen between 2.5 and 4.0 ng/mL: relation to biopsy strategy. J Urol 2001, 165:757-760.
12. Hakama M, Stenman UH, Aromaa A, et al.: Validity of the prostate-specific antigen test for prostate cancer screening: follow-up study with a bank of 21,000 sera in Finland. J Urol 2001, 166:2189-2192.
13. Recker F, Kwiatkowski MK, Huber A, et al.: Prospective detection of clinically relevant prostate cancer in the prostate-specific antigen range 1 to 3 ng./mL. combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001, 166:851-855.
14. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer [see comment]. N Engl J Med 2003, 349:215-224.
15. Thompson IM, Pauler DK, Goodman PJ, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter [see comment]. N Engl J Med 2004, 350:2239-2246
16. [Erratum appears in N Engl J Med 2004, 351:1470]. This paper highlights the prevalence of prostate cancer in men with a PSA of 4 ng/mL or less.
17. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
18. Stamey TA: The era of serum prostate-specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 2004, 94:963-964.
19. Stamey TA, Caldwell M, McNeal JE, et al.: The prostate-specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004, 172:1297-1301.
20. Carter HB, Pearson JD, Metter EJ, et al.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease [see comment]. JAMA 1992, 267:2215-2220.
21. Benson MC, Whang IS, Olsson CA, et al.: The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992, 147:817-821.
22. Oesterling JE, Jacobsen SJ, Chute CG, et al.: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges [see comment]. JAMA 1993, 270:860-864.
23. Partin AW, Catalona WJ, Southwick PC, et al.: Analysis of percent-free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996, 48:55-61.
24. Brawer MK, Beatie J, Wener MH, et al.: Screening for prostatic carcinoma with prostate-specific antigen: results of the second year. J Urol 1993, 150:106-109.
25. Brawer MK, Chetner MP, Beatie J, et al.: Screening for prostatic carcinoma with prostate-specific antigen. J Urol 1992, 147:841-845.
26. Catalona WJ, Smith DS, Ratliff TL, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer [see comment]. N Engl J Med 1991, 324:1156-1161
27. [Erratum appears in N Engl J Med 1991, 325:1324].
28. Cooner WH, Mosley BR, Rutherford CL Jr, et al.: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate-specific antigen. J Urol 1990, 143:1146-1152; discussion 1152-1144.
29. Terris MK, Stamey TA: Utilization of polyclonal serum prostate-specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. Br J Urol 1994, 73:61-64.
30. Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound-guided transrectal core biopsies of the prostate. J Urol 1989, 142:71-75.
31. Hernandez J, Thompson IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004, 101:894-904.
32. Thompson IM, Ankerst DP, Chi C, et al.: Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005, 294:66-70.
33. Holmes EH: PSMA-specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 2001, 10:511-519.
34. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995, 62:552-558.
35. Manyak MJ, Hinkle GH, Olsen JO, et al.: Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999, 54:1058-1063.
36. Babaian RJ, Sayer J, Podoloff DA, et al.: Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol 1994, 152:1952-1955.
37. Bermejo CE, Coursey J, Basler J, et al.: Histologic confirmation of lesions identified by Prostascint scan following definitive treatment. Urol Oncol 2003, 21:349-353.
38. Fradet Y, Saad F, Aprikian A, et al.: uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004, 64:311-316.
39. Brawn PN, Johnson EH, Kuhl DL, et al.: Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993, 71:2569-2573.
40. Hoffman RM, Gilliland FD, Eley JW, et al.: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001, 93:388-395.
41. Powell IJ: Prostate cancer in the African American: Is this a different disease? Semin Urol Oncol 1998, 16:221-226.
42. Stanford JL, Ostrander EA: Familial prostate cancer. Epidemiol Rev 2001, 23:19-23.
43. Lichtenstein P, Holm NV, Verkasalo PK, et al.: Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland [see comment]. N Engl J Med 2000, 343:78-85.
44. Gonzalgo ML, Isaacs WB: Molecular pathways to prostate cancer. J Urol 2003, 170:2444-2452.
45. Hsing AW, Chokkalingam AP, Gao YT, et al.: Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002, 11:337-341.
46. Nam RK, Elhaji Y, Krahn MD, et al.: Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000, 164:567-572.
47. Giovannucci E, Stampfer MJ, Krithivas K, et al.: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997, 94:3320-3323
48. [Erratum appears in Proc Natl Acad Sci U S A 1997, 94:8272].
49. Makridakis NM, di Salle E, Reichardt JK: Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000, 10:407-413.
50. Rebbeck TR: More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2000, 92:76.
51. Walker AH, Jaffe JM, Gunasegaram S, et al.: Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998, 12:289.
52. Ingles SA, Coetzee GA, Ross RK, et al.: Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998, 58:1620-1623.
53. Kibel AS, Isaacs SD, Isaacs WB, Bova GS: Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 1998, 160:1405-1409.
54. Beer TM, Evans AJ, Hough KM, et al.: Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis 2002, 5:22-27.
55. Verma M, Srivastava S: New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 2003, 163:72-84; discussion 264-266.
56. Zheng Y, Xu Y, Ye B, et al.: Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003, 98:2576-2582.
57. Cazares LH, Adam BL, Ward MD, et al.: Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002, 8:2541-2552.
58. Grizzle WE, Semmes OJ, Basler J, et al.: The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol Oncol 2004, 22:337-343. This paper highlights the techniques of the EDRN SELDI prostate cancer biomarker validation study. The methodologies used for this will prove useful for guiding future biomarker studies.
59. Ardekani AM, Liotta LA, Petricoin EF 3rd: Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002, 2:312-320.
60. Oesterling JE, Chan DW, Epstein JI, et al.: Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988, 139:766-772.
61. Li J, Zhang Z, Rosenzweig J, et al.: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
62. Zhukov TA, Johanson RA, Cantor AB, et al.: Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003, 40:267-279.
63. Banez LL, Prasanna P, Sun L, et al.: Diagnostic potential of serum proteomic patterns in prostate cancer [see comment]. J Urol 2003, 170:442-446.